Taiwan Liposome Company, Ltd. (TLC)
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Our extensive experience with liposome science allows us to combine onset speed and benefit duration, and to improve API concentrations at target tissues while decreasing unwanted systemic exposures. Our BioSeizer lipid formulation technology enables both local sustained release and fast onset of APIs at the site of disease or injury with increased pharmacokinetic (PK) control, made possible by customization of lipid layers. BioSeizer is utilized in our TLC599, TLC590 and TLC399 programs.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About Us
Our NanoX® active drug loading technology enables better toxicity profiles, potential for reduced dosing frequency, and enhanced distribution of liposome-encapsulated APIs to the desired site. NanoX® is capable of loading over 50 various compounds and is applied to our TLC178 program.
Our technologies can be used with a broad range of APIs and enable a simplified and scalable manufacturing process. Because our product candidates use already approved APIs, we are eligible to utilize the streamlined 505(b)(2) regulatory pathway for approval in the United States. We have used our proprietary technology platforms to assemble a diverse product candidate portfolio that targets significant areas of unmet medical need in pain management, ophthalmology, oncology, and infectious diseases.
Our team has hundreds of years of combined experience in lipids and other life sciences products and drug development expertise. Their accomplishments include gaining the approval of two lipid formulation products marketed in Asia. We are headquartered in Taipei, Taiwan, with offices in Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco and Tokyo.
History
- InspirMed, Inc., a TLC subsidiary specializing in inhalable liposome formulation programs, is established
- Ampholipad™ approved and launched in India
- Partnership with Endo
- Voluntary delisting from Nasdaq and Taipei Exchange
- TLC is listed on the Nasdaq Global Market (ticker: TLC)
- TLC initiates EXCELLENCE Phase III trial of TLC599 in knee osteoarthritis pain
- Phase II trial of TLC590 in bunionectomy successfully completed
- TLC ranks Top 5%in Corporate Governance Evaluations six years running
- TLC178 is designated by the US FDA as an orphan drug for the treatment of soft tissue sarcoma and a rare pediatric disease in the treatment of rhabdomyosarcoma.
- TLC receives a top 5% ranking in Corporate Governance Evaluation among all TPEx-listed companies
- TLC opens subsidiary offices in Australia, Hong Kong, Shanghai and Japan
- Ampholipad™ is approved and launched in Taiwan
- TLC388 is accepted into the Green Path accelerated development pathway by the CFDA
- TLC is listed on the Taipei Exchange (TWO: 4152)
- TLC388 obtains orphan drug designation for development in hepatocellular carcinoma (HCC) in both Europe and the United States
- TLC establishes subsidiary offices in Leiden, the Netherlands
- TLC establishes subsidiary offices in San Francisco, CA
- TLC headquarter established in Nangang Software Park, Taipei, Taiwan
- Lipo-Dox is approved for treatment of breast cancer, ovarian caner, AIDS-related Kaposi's sarcoma and multiple myeloma
- TLC is founded and begins development of Lipo-Dox
Social Responsibility
Corporate Social Responsibility
The Company follows Corporate Governance Best-Practice Principles, fostering general shareholders, board, functional committees and internal controls as significant governance factors. In order to uphold corporate social responsibilities, the Company established 'Code of Operation Integrity,' 'Code Of Ethics For Directors And Managerial officer,' and ' Employee Code of Conduct.' The up-to-date contents of regulation are published on MOPS and official corporate website. Besides, leading by President Office and Department of General Administration, the whole team aims at fostering social responsibilities, reporting to board meetings, and organizing internal trainings for board members and employees. The Company will comply with 'Corporate Social Responsibility Best Practice Principles for TWSE/GTSM-Listed Companies' and relevant laws and bylaws to ensure sustainable development and further pursue on corporate social responsibilities.
Enhancing Disclosure of Corporate Social Responsibility Information
The Company reports its relevant information and material information on MOPS and discloses information of corporate social responsibility on Company’s website and annual report. From 2013, the Company issues Corporate Social Responsibility Report, in accordance with GRI Standards Sustainability Report, on MOPS and its website.